Fortress Biotech Inc（FBIO）股票分析FBIOFortress Biotech Inc

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Fortress Biotech Inc (FBIO) is a good buy right now due to its current price of $1.86, which is significantly below the analyst price target of $5, indicating a potential upside of over 168%. Additionally, the company's forward P/E ratio is 1.232, suggesting it is undervalued relative to its earnings potential. The main risk is its RSI of 37.068, indicating it is in oversold territory, which could lead to further price volatility.

2 analysts cover FBIO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.75.